Lipid Efficacy Study (0524B-022)(COMPLETED)

A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia

This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.

Inclusion Criteria:

• Patients 18 to 85 years of age with primary hypercholesterolemia or mixed hyperlipidemia
• LDL-C between 130 and 190 mg/L (Category I) and 130 and 160 mg/L (Category II) and triglycerides </= 350 mg/dL.

Exclusion Criteria:

• A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study
• Patients with <80% compliance
• Patients with certain medical conditions
• Patients taking certain concomitant medications and/or with unstable doses of medications
• Or those with a history of CHD/CHD equivalent or diabetes